803 related articles for article (PubMed ID: 18389089)
41. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Malan DR; Krantz E; David N; Wirtz V; Hammond J; McGrath D;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):161-7. PubMed ID: 17971713
[TBL] [Abstract][Full Text] [Related]
42. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
[TBL] [Abstract][Full Text] [Related]
43. Atazanavir: a new protease inhibitor to treat HIV infection.
Musial BL; Chojnacki JK; Coleman CI
Am J Health Syst Pharm; 2004 Jul; 61(13):1365-74. PubMed ID: 15287232
[TBL] [Abstract][Full Text] [Related]
44. [Clinical utility of atazanavir].
Ribera Pascuet E; Curran A
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
[TBL] [Abstract][Full Text] [Related]
46. Atazanavir: simplicity and convenience in different scenarios.
Pérez-Elías MJ
Expert Opin Pharmacother; 2007 Apr; 8(5):689-700. PubMed ID: 17376023
[TBL] [Abstract][Full Text] [Related]
47. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
von Hentig N; Kaykhin P; Stephan C; Babacan E; Stürmer M; Staszewski S; Lötsch J
Antimicrob Agents Chemother; 2008 Jun; 52(6):2273-5. PubMed ID: 18411323
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
[TBL] [Abstract][Full Text] [Related]
49. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
[TBL] [Abstract][Full Text] [Related]
50. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
51. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
[TBL] [Abstract][Full Text] [Related]
53. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
54. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
[TBL] [Abstract][Full Text] [Related]
55. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
[TBL] [Abstract][Full Text] [Related]
56. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
[TBL] [Abstract][Full Text] [Related]
58. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
59. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
60. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]